• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters
Displaying 54-68 of 133 results

1057 Exhibit: MYLAN EX 1057 Final Office Action of March 6, 2013 in US Patent Ap...

Document IPR2017-01034, No. 1057-48 Exhibit - MYLAN EX 1057 Final Office Action of March 6, 2013 in US Patent Appl No 13617,138 (P.T.A.B. Mar. 9, 2017)

cite Cite Document
Analyze

1049 Exhibit: MYLAN EX 1049 Uceris¿¿ Instant Savings Program

Document IPR2017-01034, No. 1049-40 Exhibit - MYLAN EX 1049 Uceris¿¿ Instant Savings Program (P.T.A.B. Mar. 9, 2017)

cite Cite Document
Analyze

1048 Exhibit: MYLAN EX 1048 Santarus¿¿¿ CEO Discusses FDA Approval Of UCER...

Document IPR2017-01034, No. 1048-39 Exhibit - MYLAN EX 1048 Santarus¿¿¿ CEO Discusses FDA Approval Of UCERIS (P.T.A.B. Mar. 9, 2017)

cite Cite Document
Analyze

1032 Exhibit: MYLAN EX 1032 Entocort¿¿ EC Highlights of Prescribing Information

Document IPR2017-01034, No. 1032-23 Exhibit - MYLAN EX 1032 Entocort¿¿ EC Highlights of Prescribing Information (P.T.A.B. Mar. 9, 2017)

cite Cite Document
Analyze

1035 Exhibit: MYLAN EX 1035 Flanders et al

Document IPR2017-01034, No. 1035-26 Exhibit - MYLAN EX 1035 Flanders et al (P.T.A.B. Mar. 9, 2017)

cite Cite Document
Analyze

1006 Exhibit: MYLAN EX 1006 Declaration of Anthony Palmieri III, PhD, RPh

Document IPR2017-01034, No. 1006-3 Exhibit - MYLAN EX 1006 Declaration of Anthony Palmieri III, PhD, RPh (P.T.A.B. Mar. 9, 2017)

cite Cite Document
Analyze

1062 Exhibit: MYLAN EX 1062 N Robinson, Surface Interaction of Lecithin and Lys...

Document IPR2017-01034, No. 1062-53 Exhibit - MYLAN EX 1062 N Robinson, Surface Interaction of Lecithin and Lysolecithin, J of Pharmacy and Pharmacology (P.T.A.B. Mar. 9, 2017)

cite Cite Document
Analyze

1033 Exhibit: MYLAN EX 1033 Svensson et al

Document IPR2017-01034, No. 1033-24 Exhibit - MYLAN EX 1033 Svensson et al (P.T.A.B. Mar. 9, 2017)

cite Cite Document
Analyze

1041 Exhibit: MYLAN EX 1041 US Patent No 5,643,602

Document IPR2017-01034, No. 1041-32 Exhibit - MYLAN EX 1041 US Patent No 5,643,602 (P.T.A.B. Mar. 9, 2017)

cite Cite Document
Analyze

1034 Exhibit: MYLAN EX 1034 US Patent No 6,395,300

Document IPR2017-01034, No. 1034-25 Exhibit - MYLAN EX 1034 US Patent No 6,395,300 (P.T.A.B. Mar. 9, 2017)

cite Cite Document
Analyze

1010 Exhibit: MYLAN EX 1010 US Patent No 6,239,120

Document IPR2017-01034, No. 1010-7 Exhibit - MYLAN EX 1010 US Patent No 6,239,120 (P.T.A.B. Mar. 9, 2017)

cite Cite Document
Analyze

1002 Exhibit: MYLAN EX 1002 US Patent No 8,784,888

Document IPR2017-01034, No. 1002-2 Exhibit - MYLAN EX 1002 US Patent No 8,784,888 (P.T.A.B. Mar. 9, 2017)

cite Cite Document
Analyze

1026 Exhibit: MYLAN EX 1026 Handbook of Pharmaceutical Excipients

Document IPR2017-01034, No. 1026 Exhibit - MYLAN EX 1026 Handbook of Pharmaceutical Excipients (P.T.A.B. Mar. 9, 2017)

cite Cite Document
Analyze

1023 Exhibit: MYLAN EX 1023 US Patent No 5,342,625

Document IPR2017-01034, No. 1023 Exhibit - MYLAN EX 1023 US Patent No 5,342,625 (P.T.A.B. Mar. 9, 2017)

cite Cite Document
Analyze

1044 Exhibit: MYLAN EX 1044 See A Blume, B Arnold, HU Weltzien,

Document IPR2017-01034, No. 1044 Exhibit - MYLAN EX 1044 See A Blume, B Arnold, HU Weltzien, (P.T.A.B. Mar. 9, 2017)

cite Cite Document
Analyze
<< 1 2 3 4 5 6 7 8 9 10 >>